@brettboettcher1 7) Here is the link to a double-blind RCT (gold standard of research in medicine) on LDL or "bad" cholesterol and detrimental effects on health. https://t.co/RkoMKMYsE1
@ErinMichos @albosta_mike @JelaniGrantMD Ezemtimibe seems safe and effective. @neeche41 Bempedoic acid is a toxic substance that also reduces CV events a teeny, tiny amount, but whose absolute harms intrinsically outweigh any benefits https://t.co/CIGr
RT @cardiomet_CE: 18b) We addressed that question in the #IMPROVE_IT trial (a #secondary_prevention trial) – and found the benefit with add…
18b) We addressed that question in the #IMPROVE_IT trial (a #secondary_prevention trial) – and found the benefit with adding ezetimibe was exactly what one would have expected based on the amount of LDL reduction. 🔓 https://t.co/Uo1lxSmfJB https://t.co/BpW
RT @syuichiao89: 答えは薬事日報さんの連載「エビデンスのピットフォール」で( *´艸`)
答えは薬事日報さんの連載「エビデンスのピットフォール」で( *´艸`)
IMPROVE-IT試験の一次アウトカムで示されたNNTは50人である。 https://t.co/WoRPT7vS4m なお、プラバスタチンのMEGA試験ではNNT119人であった。NNTが2桁というエゼチミブは、すごい薬と言ってよいだろうか NNTの解釈をめぐるピットフォールを簡潔に述べよ。
#脂質異常症 2次予防のエゼチミブ併用のエビデンス これも結論から言うと超微妙 まずよく根拠として出されるIMPROVE-IT試験 そもそもシンバスタチン+エゼチミブ vs シンバスタチンって中強度スタチンにしちゃってるから、前提から微妙 しかもHR0.94って効果的にもすごい微妙 https://t.co/cJcXbkNZL0
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
RT @daphnebarq: Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N…
Buenísima clase del tratamiento farmacológico de las dislipidemias. @RZubiranS Clase completa: https://t.co/G6oRctd6Op N Engl J Med 2015;372:2387-97 DOI: 10.1056/NEJMoa1410489 https://t.co/8VMuaSY3wE https://t.co/SNkOwdQC8P
@ophirnahum99 תודה אופיר! אני לא יודע לגבי חברות מסחריות, אבל בעשורים האחרונים פורסמו המון עבודות שהראו שככל שהורידו את רמות ה-LDL יותר, כך הסיכון להתקפי לב ולשבץ פחת. יש כל כך הרבה עבודות כאלה, ככה שזה מאוד משכנע הנה למשל 2 עבודות נבחרות: https://t.co/BI
@MattMadore576 @PFinanceiros https://t.co/1OJqgbDvtz In the accelerate discussion they mention this trial that started to see a difference at 1 year. However, ApoB at baseline was higher than accelerate (92.7 vs 78.6). Diabetes, previous MI % and hyperten
@TexCIS @luisbaram Certainly the question about whether Statins had a unique mechanism that reduced cardiovascular risk and whether other classes of medication reduced risk at all was an evidence free zone until this study was published in 2015 https://t.
@UtahIMCMRs Journal club? Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes https://t.co/rbBGI8Zx1H
RT @cardiomet_CE: 21) In the #IMPROVE_IT CV outcomes study, led by @cardiomet_ce author @cpcannon (🔓https://t.co/9jnjHx1oWJ), #ezetimibe ⬇️…
RT @cardiomet_CE: 21) In the #IMPROVE_IT CV outcomes study, led by @cardiomet_ce author @cpcannon (🔓https://t.co/9jnjHx1oWJ), #ezetimibe ⬇️…
RT @cardiomet_CE: 21) In the #IMPROVE_IT CV outcomes study, led by @cardiomet_ce author @cpcannon (🔓https://t.co/9jnjHx1oWJ), #ezetimibe ⬇️…
21) In the #IMPROVE_IT CV outcomes study, led by @cardiomet_ce author @cpcannon (🔓https://t.co/9jnjHx1oWJ), #ezetimibe ⬇️ LDL-C by a further 24% when added to #statins ➡️absolute risk ⬇️ of 2% in the primary composite endpoint of #CV mortality, major CV ev
@CheriVanders @soy_product @ShawnNeedham2 @ifixhearts Very scientific to claim evidence is manipulated before you even see it... It was a 2% reduction with Ezetimibe when added to a statin (ezetimibe is not a statin). ~170 fewer patients out of 18k reache
この知見は、過去の試験でスタチン以外の脂質改善薬を追加しても、有意な効果が得られなかったという点で注目に値します。 https://t.co/uXHsvaznqU Ezetimibe added to statin therapy after acute coronary syndromes.
参照:N Engl J Med 2015; 372:2387-2397 https://t.co/ICTYaBfkYk (上記を含む複数のRCT) ※UpToDateにもまとめられています ”Low-density lipoprotein cholesterol lowering with drugs other than statins and PCSK9 inhibitors”
RT @cardiomet_CE: 7) A large trial of combination therapy for CV event reduction was IMPROVE-IT (🔓https://t.co/Uo1lxSmfJB) compared statin…
7) A large trial of combination therapy for CV event reduction was IMPROVE-IT (🔓https://t.co/Uo1lxSmfJB) compared statin alone vs. statin+ #ezetimibe. Primary end point was a composite of #CV death, nonfatal #MI, unstable angina, or coronary revasc.
RT @cardiomet_CE: 35) Even a subsequent #RCT showing that ezetimibe improved cardiac outcomes did not totally fix ezetimibe’s damaged reput…
35) Even a subsequent #RCT showing that ezetimibe improved cardiac outcomes did not totally fix ezetimibe’s damaged reputation. IMPROVE-IT (🔓https://t.co/Uo1lxSmfJB) randomized pts w/ #ACS to simvastatin 40 w/ or w/o ezetimibe.
Taking @nationallipid self-assessment program for elective. 👍👍 resource for clinical lipidology and bonus lit review with each question 👉eze+statin IMPROVE-IT https://t.co/rbBGI8HVD7 MA of ezetimibe + statin https://t.co/IJHIninh38 Eze/Simva vs. atorva ht
RT @cardiomet_CE: 10) In fact, residual risk persists despite #statin+#ezetimibe & average LDL=54 mg/dL. Only ~1/16 events were prevented w…
RT @cardiomet_CE: 10) In fact, residual risk persists despite #statin+#ezetimibe & average LDL=54 mg/dL. Only ~1/16 events were prevented w…
RT @cardiomet_CE: 10) In fact, residual risk persists despite #statin+#ezetimibe & average LDL=54 mg/dL. Only ~1/16 events were prevented w…
RT @cardiomet_CE: 10) In fact, residual risk persists despite #statin+#ezetimibe & average LDL=54 mg/dL. Only ~1/16 events were prevented w…
10) In fact, residual risk persists despite #statin+#ezetimibe & average LDL=54 mg/dL. Only ~1/16 events were prevented with #simvastatin 40+ezetimibe (comp to simva 40). Do we need STILL more potent therapies to achieve EVEN LOWER LDLs? @cpcannon agai
@agargmd not sure which trial ur referring to, IMPROVE-IT was 0.89 to 0.99 https://t.co/06nJBUuEca
@Rx_Ed Granted it is a composite outcome but they did study ezetimibe + simva vs. simva alone https://t.co/KhgAkpPKzs
Autant je me bats contre les ttt pour les LDL a 1,63 aux gens sans FDR, autant, on a suffisamment de preuve pour dire que l’adjonction d’ezetimibe à une statine pour avoir un LDL très bas chez le coronarien est bénéfique. https://t.co/GTonzKIHoy
Pues te dejo unos cuántos de ensayos clínicos y metanálisis que demuestran precisamente lo contrario: - Prove-it (ensayo clínico del 2004: https://t.co/xNrn8GlCSc) - Improve it (ensayo clínico del 2015 https://t.co/hpaI2ZXfJD) - Fourier (ensayo clínico del
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes https://t.co/koJGOFKIoc 後輩より質問 「PCI後でスタチン内服中、LDL-C49の患者にエゼチミブ追加する必要あるの?」 ⇒LDL-Cが推奨範囲内でもエゼチミブを追加することで心血管転帰をよりいっそう改善させる
Impact of non-statins (i.e. ezetimibe) on ASCVD in the IMPROVE-IT trial: https://t.co/KI80AW4UNC
IMPROVE-ITをさらにPediatricsにExpandさせるコンセプトって、、、 https://t.co/lBRRkFO9IP
@Pharma_blog 後で考察された薬理学的作用はその通りだと思います!! エビデンスは、スタチンにエゼチミブ加えてみました!!的なノリ。Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes | NEJM https://t.co/8kYJd6ZIaF
RT @adamcifu: IMHO, the results of IMPROVE-IT are more frequently inappropriately extrapolated from than those from any other trial I can t…
@ProfAsifAhmed @MaijaRuuth This meta analysis pretty much says the same Asif https://t.co/wWOstpm1Tq and of course ezetimibe, which is now generic and cheap, has NICE approval and the IMPROVE-IT RCT https://t.co/GvwTJwW0yC
RT @AudreyBJernigan: #MRPearls IMPROVE-IT trial @NEJM (2015): ezetimibe➕ mod-intensity statin =⬇️ CV mortality, major CV event or nonfata…
RT @AudreyBJernigan: #MRPearls IMPROVE-IT trial @NEJM (2015): ezetimibe➕ mod-intensity statin =⬇️ CV mortality, major CV event or nonfata…
#MRPearls IMPROVE-IT trial @NEJM (2015): ezetimibe➕ mod-intensity statin =⬇️ CV mortality, major CV event or nonfatal stroke vs statin alone in patients with recent ACS @CoryRTrankle @AbbateAntonio @JCHillyard @DrJaredDyer @chrisLyoungmd @ktwaybill htt
Example: they cite IMPROVE-IT as evidence. https://t.co/acdPJAfkGf But IMPROVE-IT was of secondary prevention. And see their baseline data… not representative for what I’m asking. https://t.co/abztdspvta
RT @brophyj: Issue not only generalizability but also effect size. Study protocol had to be modified to 2X original and ultimately 350 pt y…
RT @adamcifu: IMHO, the results of IMPROVE-IT are more frequently inappropriately extrapolated from than those from any other trial I can t…
Issue not only generalizability but also effect size. Study protocol had to be modified to 2X original and ultimately 350 pt years of treatment req’d to prevent 1 composite outcome.
RT @adamcifu: IMHO, the results of IMPROVE-IT are more frequently inappropriately extrapolated from than those from any other trial I can t…
RT @adamcifu: This discussion is why twitter can be great. Thanks to all for extending the discussion, with great references. https://t.co/…
RT @adamcifu: IMHO, the results of IMPROVE-IT are more frequently inappropriately extrapolated from than those from any other trial I can t…
This discussion is why twitter can be great. Thanks to all for extending the discussion, with great references.
RT @adamcifu: IMHO, the results of IMPROVE-IT are more frequently inappropriately extrapolated from than those from any other trial I can t…
En mi humilde opinión, los resultados de IMPROVE-IT son los que con más frecuencia han sido extrapolados inapropiadamente, más que los de cualquier otro ensayo que se me ocurra. Sólo lo comento.
RT @adamcifu: IMHO, the results of IMPROVE-IT are more frequently inappropriately extrapolated from than those from any other trial I can t…
RT @adamcifu: IMHO, the results of IMPROVE-IT are more frequently inappropriately extrapolated from than those from any other trial I can t…
RT @adamcifu: IMHO, the results of IMPROVE-IT are more frequently inappropriately extrapolated from than those from any other trial I can t…
Definitely. https://t.co/Dw4vZRFp7i
RT @adamcifu: IMHO, the results of IMPROVE-IT are more frequently inappropriately extrapolated from than those from any other trial I can t…
IMHO, the results of IMPROVE-IT are more frequently inappropriately extrapolated from than those from any other trial I can think of. Just saying. https://t.co/DSHgzdkiUk
@NadeenFaza @IAmDrIbrahim It's over 50.* * = IMPROVE-IT -- admittedly for ACS in the past ~week which does not describe my patient -- enrolled people with LDL-c >= 50: https://t.co/4NweX9iDEN
@Nelle_Lindow Many medical research studies are funded by #pharma and you can see a huge financial bias. For example, how did the drug Zetia come to be approved when its confidence interval crosses 0.99? Ask why. https://t.co/s3E0COxjAg https://t.co/MaUl
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes | NEJM https://t.co/Ka4Us6l7xv
IMPROVE-IT was ezetimibe 10 + simvastatin vs simva alone. A small extra reduction in LDL and a matching small extra reduction in events. The investigators emphasized how it matched the statin trials: https://t.co/BRjW1t3bCd https://t.co/ZEsVysCL0n
@MrChylo ¿Evidencia de qué, Javier? ¿No te parecen válidos los ensayos clínicos multicéntricos, o los meta-análisis de ensayos clínicos? https://t.co/y1CNSYzsVB https://t.co/Zeyzla4LFZ ...una pena desinformar así a la gente! @secardiologia
RT @quequesierra: La de aplausos que debería llevarse este fármaco... hay fármacos más aplaudidos con un 7% de reducción relativa... ezetim…